Last reviewed · How we verify
FNC
FNC is a small molecule that targets the SGLT2 receptor.
FNC is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | FNC |
|---|---|
| Also known as | Azvudine, Azvudine placebo |
| Sponsor | Henan Genuine Biotech Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
FNC works by inhibiting the SGLT2 receptor, which reduces glucose reabsorption in the kidneys and lowers blood glucose levels. This mechanism is particularly useful for treating type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Aluvia (PHASE1)
- A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Dolutegravir Sodium Tablets (DTG) (PHASE1)
- A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Tenofovir Alafenol Fumarate Tablets (TAF) (PHASE1)
- A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Rifampicin Capsules (RIF) (PHASE1)
- A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Itraconazole Capsules (ICZ) (PHASE1)
- A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Rilpivirine Tablets (RPV) (PHASE1)
- Nurse-led Family and Network Consultations (NA)
- Evaluate Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19 in China (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FNC CI brief — competitive landscape report
- FNC updates RSS · CI watch RSS
- Henan Genuine Biotech Co., Ltd. portfolio CI